GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (OTCPK:KNBIF) » Definitions » Cyclically Adjusted PS Ratio

Kane Biotech (Kane Biotech) Cyclically Adjusted PS Ratio : 10.11 (As of May. 17, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Kane Biotech Cyclically Adjusted PS Ratio?

As of today (2024-05-17), Kane Biotech's current share price is $0.10105. Kane Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.01. Kane Biotech's Cyclically Adjusted PS Ratio for today is 10.11.

The historical rank and industry rank for Kane Biotech's Cyclically Adjusted PS Ratio or its related term are showing as below:

KNBIF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.5   Med: 13   Max: 23
Current: 12.86

During the past years, Kane Biotech's highest Cyclically Adjusted PS Ratio was 23.00. The lowest was 5.50. And the median was 13.00.

KNBIF's Cyclically Adjusted PS Ratio is ranked worse than
74.85% of 513 companies
in the Biotechnology industry
Industry Median: 5.51 vs KNBIF: 12.86

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kane Biotech's adjusted revenue per share data for the three months ended in Dec. 2023 was $-0.011. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.01 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kane Biotech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Kane Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech Cyclically Adjusted PS Ratio Chart

Kane Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.81 12.71 13.03 7.81 7.35

Kane Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.81 10.89 7.32 5.90 7.35

Competitive Comparison of Kane Biotech's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Kane Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Cyclically Adjusted PS Ratio falls into.



Kane Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kane Biotech's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.10105/0.01
=10.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Kane Biotech's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.011/125.0724*125.0724
=-0.011

Current CPI (Dec. 2023) = 125.0724.

Kane Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 98.604 0.000
201406 0.000 99.473 0.000
201409 0.001 99.394 0.001
201412 0.001 98.367 0.001
201503 0.001 99.789 0.001
201506 0.001 100.500 0.001
201509 0.000 100.421 0.000
201512 0.001 99.947 0.001
201603 0.001 101.054 0.001
201606 0.002 102.002 0.002
201609 0.001 101.765 0.001
201612 0.003 101.449 0.004
201703 0.013 102.634 0.016
201706 0.002 103.029 0.002
201709 0.001 103.345 0.001
201712 -0.005 103.345 -0.006
201803 0.001 105.004 0.001
201806 0.001 105.557 0.001
201809 0.001 105.636 0.001
201812 0.002 105.399 0.002
201903 0.006 106.979 0.007
201906 0.002 107.690 0.002
201909 0.003 107.611 0.003
201912 0.005 107.769 0.006
202003 0.003 107.927 0.003
202006 0.002 108.401 0.002
202009 0.003 108.164 0.003
202012 0.002 108.559 0.002
202103 0.003 110.298 0.003
202106 0.002 111.720 0.002
202109 0.004 112.905 0.004
202112 0.003 113.774 0.003
202203 0.004 117.646 0.004
202206 0.006 120.806 0.006
202209 0.004 120.648 0.004
202212 -0.010 120.964 -0.010
202303 0.004 122.702 0.004
202306 0.004 124.203 0.004
202309 0.004 125.230 0.004
202312 -0.011 125.072 -0.011

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kane Biotech  (OTCPK:KNBIF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kane Biotech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Kane Biotech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech (Kane Biotech) Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, DermaKB and DermaKB Biofilm are trademarks of the company. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.